


Amendment to the Claims.


Please amend claims 1, 2, 14, 15, 28 and 30 and add claims 36-39 as set forth below.


Listing of Claims. This listing replaces any previous listing.

1 (Currently Amended). A soluble purified polypeptide comprising the amino acid sequence of SEQ ID NO: 10-4; ~~wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2);~~ wherein said polypeptide is soluble at a 34 mg/ml concentration in 25 mM Hepes-potassium hydroxide, pH 7.5, 0.15M potassium chloride, 1 mM EDTA, 0.03% sodium azide and 5 mM DTT buffer; and wherein said polypeptide is capable of binding a member selected from the group consisting of p53,




~~and~~






and




2 (Currently Amended). ~~The polypeptide according to claim 1, wherein said polypeptide comprises~~ A soluble purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12.


3-13 (Cancelled).

14 (Currently Amended). A compound represented by a structural formula which is selected from the group consisting of




and





_____ and _____





15 (Currently Amended). A soluble polypeptide-compound complex comprising the compound according to claim 14 and a polypeptide complexed to it, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:

~~10 -4, wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); and wherein said polypeptide is soluble at a 34 mg/ml concentration in 25 mM Hepes-potassium hydroxide, pH 7.5, 0.15M potassium chloride, 1 mM EDTA, 0.03% sodium azide and 5 mM DTT buffer.~~

16 -27 (Cancelled).

28 (Currently Amended). A crystal comprising a complex between a polypeptide consisting of having the amino acid sequence of SEQ ID NO: 10 and a compound represented by the structural formula:







_____, wherein said crystal is in space group $P2_12_12_1$ and comprises unit cell dimensions $a=37.999 \text{ \AA}$, $b=45.333 \text{ \AA}$, $c=63.999 \text{ \AA}$, where $\alpha=\beta=\gamma=90^\circ$.

29 (Cancelled).

30 (Currently Amended). A crystal comprising a complex between a polypeptide consisting of ~~having~~ the amino acid sequence of SEQ ID NO: 6 and a compound represented by the structural formula:



_____, wherein said crystal is in space group $P2_12_12_1$ and comprises unit cell dimensions $a=41.1 \text{ \AA}$, $b=42.7 \text{ \AA}$, $c=53.777 \text{ \AA}$, where $\alpha=\beta=\gamma=90^\circ$.

31-33 (Cancelled).

34 (Previously Presented). The crystal of claim 28 wherein the complex in said crystal is characterized by structural coordinates set forth in Table 3.

35 (Previously Presented). The crystal of claim 30 wherein the complex in said crystal is characterized by structural coordinates set forth in Table 4.

36 (New). The polypeptide of claim 2 comprising the amino acid sequence set forth in SEQ ID NO: 6.

37 (New). The polypeptide of claim 2 comprising the amino acid sequence set forth in SEQ ID NO: 8.

38 (New). The polypeptide of claim 2 comprising the amino acid sequence set forth in SEQ ID NO: 10.

39 (New). The polypeptide of claim 2 comprising the amino acid sequence set forth in SEQ ID NO: 12.